Loading
Founder of cancer epigenetics, showing that abnormal DNA methylation silences tumour-suppressor genes and can be reversed by drugs.
Stephen B. Baylin is the Virginia and D.K. Ludwig Professor of Oncology and Medicine at Johns Hopkins Hospital and the Sidney Kimmel Comprehensive Cancer Center. He is a founder of cancer epigenetics, having established that abnormal promoter DNA methylation silences tumour-suppressor genes in cancer and that this can be reversed by drugs. His selected paper reviews a decade of exploring the cancer epigenome and its biological and translational implications. He led early trials of low-dose azacitidine and HDAC inhibitors in solid tumours and continues to work on epigenetic therapy in lung cancer and acute myeloid leukaemia.
| Title | Journal | Year |
|---|---|---|
| A decade of exploring the cancer epigenome — biological and translational implications | Nature Reviews Cancer | 2011 |
Shares Epigenetic progenitor theory: cancer without a first mutation, Epigenetic therapy roadmap: loosening silenced genes → mutation-specific enzymes → editing the epigenome, DNA methylation profiling, Epigenetic drugs (HDAC, DNMT, EZH2, IDH, menin, BET).
Shares Epigenetic progenitor theory: cancer without a first mutation, Epigenetic therapy roadmap: loosening silenced genes → mutation-specific enzymes → editing the epigenome, Epigenetic drugs (HDAC, DNMT, EZH2, IDH, menin, BET).
Shares Azacitidine, Epigenetic drugs (HDAC, DNMT, EZH2, IDH, menin, BET), Acute myeloid leukaemia.
Shares Azacitidine, Epigenetic drugs (HDAC, DNMT, EZH2, IDH, menin, BET), Acute myeloid leukaemia.
Shares Azacitidine, DNA methylation profiling, Epigenetic drugs (HDAC, DNMT, EZH2, IDH, menin, BET), Acute myeloid leukaemia.
Shares Epigenetic therapy roadmap: loosening silenced genes → mutation-specific enzymes → editing the epigenome, Epigenetic drugs (HDAC, DNMT, EZH2, IDH, menin, BET), Acute myeloid leukaemia.
Shares Azacitidine, Epigenetic drugs (HDAC, DNMT, EZH2, IDH, menin, BET), Acute myeloid leukaemia.
Shares Azacitidine, Epigenetic drugs (HDAC, DNMT, EZH2, IDH, menin, BET), Acute myeloid leukaemia.